Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 212 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Oncofertility: Creating a Bridge Between Cancer Care and Reproductive Health December 23, 2019 Cancer in My Community: Providing Supportive Care in Serbia October 14, 2021 FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers... November 10, 2020 FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell... January 22, 2026 Load more HOT NEWS Will Ponsegromab Be a Game Changer for Cancer Cachexia? Promising Results Demostrated with Novel Subcutaneously Adminstered Envafolimab in Patients with... Farmer With Stage IV Cancer Is Too Sick To Harvest Crops... For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining
